$29.79
-0.36-1.18%
Last update: Nov 6, 4:03 PM
Vera Therapeutics Inc (VERA) Stock Price, Quote, News & History
VERANASDAQ
Vera Therapeutics Phase 3 trial data show that Trutakna significantly reduces kidney disease progression in IgA nephropathy.
You can purchase shares of Vera Therapeutics (NASDAQ:VERA) through any online brokerage.
Other companies in Vera Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).
Vera Therapeutics has a consensus price target of $64.06.
The stock price for Vera Therapeutics (NASDAQ: VERA) is $30.37 last updated November 6, 2026 at 4:03 PM EST.
There are no upcoming dividends for Vera Therapeutics.
Vera Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for Vera Therapeutics.
Vera Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion...
